Pharmaceuticals (Jul 2022)

Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality

  • Konrad Stepien,
  • Karol Nowak,
  • Natalia Kachnic,
  • Grzegorz Horosin,
  • Piotr Walczak,
  • Aleksandra Karcinska,
  • Tomasz Schwarz,
  • Mariusz Wojtas,
  • Magdalena Zalewska,
  • Maksymilian Pastuszak,
  • Bogdan Wegrzyn,
  • Jadwiga Nessler,
  • Jarosław Zalewski

DOI
https://doi.org/10.3390/ph15080919
Journal volume & issue
Vol. 15, no. 8
p. 919

Abstract

Read online

Statin use and its impact on long-term clinical outcomes in active cancer patients following acute myocardial infarction (MI) remains insufficiently elucidated. Of the 1011 consecutive acute MI patients treated invasively between 2012 and 2017, cancer was identified in 134 (13.3%) subjects. All patients were observed within a median follow-up of 69.2 (37.8–79.9) months. On discharge, statins were prescribed less frequently in MI patients with cancer as compared to the non-cancer MI population (79.9% vs. 91.4%, p p p p p p p < 0.001) independently increased long-term mortality. In MI patients, simultaneous diagnosis of an active cancer was associated with less frequently prescribed statins on discharge. Irrespective of cancer diagnosis, no statin use was found as an independent predictor of increased long-term mortality.

Keywords